Hepatitis Web Study

References

  1. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, Haussinger D. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med. 1996;334:1422-7.
    [The following link will open in a new window. PubMed Abstract]
  2. Di Marco V, Lo Iacono O, Camma C, et al. The long-term course of chronic hepatitis B. Hepatology. 1999;30:257-64.
    [The following link will open in a new window. PubMed Abstract]
  3. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65-73.
    [The following link will open in a new window. PubMed Abstract]
  4. Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol. 2006;101:1797-803.
    [The following link will open in a new window. PubMed Abstract]
  5. Tang B, Kruger WD, Chen G, et al. Hepatitis B viremia is associated with increased risk of hepatocellular carcinoma in chronic carriers. J Med Virol. 2004;72:35-40.
    [The following link will open in a new window. PubMed Abstract]
  6. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521-31.
    [The following link will open in a new window. PubMed Abstract]
  7. Yao FY, Bass NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol. 2000;33:301-7.
    [The following link will open in a new window. PubMed Abstract]
  8. Sherman M. Predicting survival in hepatitis B.Gut. 2005;54:1521-3.
    [The following link will open in a new window. PubMed Abstract]
  9. ACT-HBV Asia-Pacific Steering Committee Members. Chronic hepatitis B: treatment alert. Liver Int. 2006;26 Suppl 2):47-58.
    [The following link will open in a new window. PubMed Abstract]
  10. de Franchis R, Hadengue A, Lau G, et al. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol. 2003;39 Suppl 1:S3-25.
    [The following link will open in a new window. PubMed Abstract]
  11. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol. 2006;4:936-62.
    [The following link will open in a new window. PubMed Abstract]
  12. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45:507-39.
    [The following link will open in a new window. PubMed Abstract]
  13. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137:1-10.
    [The following link will open in a new window. PubMed Abstract]
  14. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352:2682-95.
    [The following link will open in a new window. PubMed Abstract]
  15. Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology. 2000;119:172-80.
    [The following link will open in a new window. PubMed Abstract]

[Back to Question | Back to Discussion]

CME Credit | CNE Credit | Back to Top